To all the participants in our COVID-19 vaccine trial around the world 🌏 . . . Thank You.

UPDATE: The @MHRAgovuk  issued a temporary authorization for emergency use of our #COVID19  vaccine with @BioNTech_Group  in the United Kingdom. This marks the first authorization of a vaccine to help fight the pandemic following a worldwide trial.

NEWS: @NEJM  published safety and final efficacy results from the Phase 3 trial of our #COVID19  vaccine, developed w/ @BioNTech_Group , confirming the candidate was well tolerated & demonstrated a 95% efficacy in those who participated in the trial.

NEWS: The @biontech_group '>Pfizer @BioNTech_Group #COVID19  vaccine has not been approved or licensed by the @US_FDA  but has been authorized for emergency use to prevent COVID-19 in individuals 16 & older. See conditions of use:

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. FDA but has been authorized for emergency use to prevent COVID-19 in individuals 16+. See conditions of use:

📸: The first shipment from our Kalamazoo plant. @UPS  @FedEx  . . The Pfizer-BioNTech #COVID19  vaccine has not been approved or licensed by the @US_FDA  but has been authorized for emergency use to prevent COVID-19 in individuals 16+. See conditions of use:

James knows what it takes to get our medicines and #vaccines  transported safely to patients around the globe. Nickname: “The Ice Man” 🧊 Job: Temperature Control Logistics 📦 #RealPeopleRealVoices 

NEWS: Today we announced a second agreement with the U.S. government to supply our #COVID19  vaccine, developed with @BioNTech_Group , to Operation Warp Speed. Read about the agreement here:

In additional to a #vaccine , antivirals can play an important role in fighting viruses. Our investigational #antiviral  for #COVID19  is currently in clinical trials and we are hopeful for its success.

We are closely monitoring the new strains and mutations from the virus’ variants. One of the reasons we chose mRNA technology is because of its potential flexibility, including the ability to alter the RNA sequence in the vaccine to potentially address new strains of the virus.